FGFR1 and breast carcinoma: In breast cancer, FGFR1 amplification is enriched in hormone receptor-positive (ER+) subtypes, particularly Luminal B-like (high-proliferation HR+) tumors, and closely associates with endocrine therapy resistance and poor prognosis [75,76].